GSA Capital Partners LLP Purchases New Position in Standard BioTools Inc. $LAB

GSA Capital Partners LLP purchased a new stake in Standard BioTools Inc. (NASDAQ:LAB) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,187,682 shares of the company’s stock, valued at approximately $977,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cibc World Markets Corp purchased a new stake in Standard BioTools during the fourth quarter valued at approximately $25,000. Aigen Investment Management LP purchased a new position in shares of Standard BioTools in the 4th quarter worth approximately $28,000. M&T Bank Corp purchased a new position in shares of Standard BioTools in the 4th quarter worth approximately $31,000. EntryPoint Capital LLC bought a new position in shares of Standard BioTools during the 4th quarter valued at approximately $31,000. Finally, Russell Investments Group Ltd. raised its holdings in Standard BioTools by 2,989.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock valued at $33,000 after buying an additional 24,211 shares during the period. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Standard BioTools from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, August 7th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Standard BioTools presently has a consensus rating of “Reduce” and a consensus price target of $1.35.

Standard BioTools Price Performance

Shares of NASDAQ:LAB opened at $0.66 on Wednesday. The firm has a market capitalization of $259.89 million, a PE ratio of 3.01 and a beta of 1.39. The business has a 50 day simple moving average of $0.83 and a two-hundred day simple moving average of $0.96. Standard BioTools Inc. has a 1 year low of $0.66 and a 1 year high of $1.72.

Standard BioTools (NASDAQ:LAB) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06). Standard BioTools had a negative return on equity of 7.57% and a net margin of 100.36%.The business had revenue of $20.10 million during the quarter, compared to analysts’ expectations of $20.80 million.

About Standard BioTools

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.